Thermo Fisher Scientific Inc. (TMO) Beats EPS Expectations in Q3, Slight Miss on Revenue
Thermo Fisher Scientific Inc. (NYSE: TMO) reported a revenue of $10.60 billion in the third quarter of 2024.
Editorial disclosureRead more
All reviews, research, news and assessments of any kind on The Tokenist are compiled using a strict editorial review process by our editorial team. Neither our writers nor our editors receive direct compensation of any kind to publish information on tokenist.com. Our company, Tokenist Media LLC, is community supported and may receive a small commission when you purchase products or services through links on our website. Click here for a full list of our partners and an in-depth explanation on how we get paid.
Thermo Fisher Scientific Inc. (NYSE: TMO) announced its financial results for the third quarter of 2024, showcasing a steady performance despite challenging market conditions. The company reported a revenue of $10.60 billion for the quarter, a slight increase from $10.57 billion in the same period last year.
This growth was driven by the launch of innovative products, including the Thermo Scientific Iliad scanning transmission electron microscope and the Applied Biosystems MagMAX Sequential DNA/RNA kit. These products are aimed at advancing research in materials and life sciences, contributing to the company’s robust growth strategy.
The company’s GAAP diluted earnings per share (EPS) for the quarter stood at $4.25, a decrease from $4.42 in the prior year.
However, the adjusted EPS, which excludes certain non-recurring items, was reported at $5.28, reflecting the company’s ability to maintain profitability through strategic initiatives. Thermo Fisher’s operating income for the quarter was $1.84 billion, with an operating margin of 17.3%, slightly down from 17.6% in the previous year.
Thermo Fisher Beats EPS Expectations in Q3, Falls Short on Revenue
Thermo Fisher’s third-quarter results exceeded expectations in some areas while falling short in others. The company had set an expectation for an adjusted EPS of $5.25, and it delivered $5.28, surpassing the forecast.
However, the revenue of $10.60 billion fell slightly short of the anticipated $10.63 billion, indicating a minor gap in achieving the expected sales targets.
Despite the revenue shortfall, the company’s performance was bolstered by its strategic initiatives and product launches, which have been pivotal in driving growth. The adjusted operating income was $2.36 billion, down from $2.56 billion in the same quarter last year, reflecting the challenges faced in maintaining margins.
Nonetheless, the company’s focus on core organic revenue growth and strategic partnerships has helped mitigate some of these pressures, showcasing resilience in a competitive market.
TMO Raises Full Year EPS Guidance to $21.35 to $22.07 Range
Looking ahead, Thermo Fisher has raised its full-year adjusted EPS guidance to a range of $21.35 to $22.07, up from the previous range of $21.29 to $22.07. This upward revision reflects the company’s confidence in its strategic initiatives and its ability to navigate the current economic landscape. The revenue guidance remains at $42.4 to $43.3 billion, indicating a stable outlook for the remainder of the year.
The company is poised to continue its growth trajectory by focusing on innovation and expanding its service offerings.
Disclaimer: The author does not hold or have a position in any securities discussed in the article.
Tim Fries
Tim Fries is the cofounder of The Tokenist. He has a B. Sc. in Mechanical Engineering from the University of Michigan, and an MBA from the University of Chicago Booth School of Business. Tim served as a Senior Associate on the investment team at RW Baird's US Private Equity division, and is also the co-founder of Protective Technologies Capital, an investment firm specializing in sensing, protection and control solutions.
